Business Model Canvas: Intracellular 5-HT2AR Location-Bias Drug Screening Assay
A preclinical assay service that distinguishes between compounds activating cell-surface versus intracellular 5-HT2A receptors. This allows drug developers to isolate neuroplasticity-promoting effects from hallucinogenic activity by targeting specific receptor locations within the cell.
The framework reveals a high-value, specialized B2B service model that leverages a technical gap in current psychedelic drug discovery. By shifting the focus from simple receptor binding to spatial location-bias, the venture creates a critical 'filter' for biotech firms aiming to decouple therapeutic neuroplasticity from hallucinogenic side effects.
Key Partners3
Key Activities3
Key Resources3
Value Propositions3
Customer Relationships2
Channels3
Customer Segments3
Cost Structure3
Revenue Streams3
The idea has clearly defined B2B customers (biotech startups and CROs) and a specific value proposition, making it ready for a business model mapping. · Generated 2026-09-24 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated